Goldman Sachs’s ChemoCentryx, Inc. CCXI Stock Holding History

Goldman Sachs’s Portfolio CCXI Stock Details CCXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-170,100	Closed	-$2.91M	–	6843
2021 Q3	$2.91M	Buy	170,100 +157,100	+1,208%	+$2.45M	﹤0.01%	3844
2021 Q2	$174K	Hold	13,000	–	–	﹤0.01%	5790
2021 Q1	$666K	Hold	13,000	–	–	﹤0.01%	4903
2020 Q4	$805K	Buy	13,000 +3,000	+30%	+$172K	﹤0.01%	4339
2020 Q3	$548K	Sell	10,000 -21,200	-68%	-$1.14M	﹤0.01%	4440
2020 Q2	$1.79M	Buy	+31,200	New	+$1.7M	﹤0.01%	3534
2013 Q4	–	Sell	-5,800	Closed	-$32K	–	6844
2013 Q3	$32K	Buy	+5,800	New	+$62.7K	﹤0.01%	6373

Other funds holding CCXI

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Goldman Sachs's CCXI Position: Q4 2022 in Review

Goldman Sachs sold out of ChemoCentryx, Inc. (CCXI) in Q4 2022, closing a stake of 5,616,301 shares — an estimated $290M sold.

Goldman Sachs first reported a position in CCXI in Q3 2013 and held it in 31 quarters. The position peaked at $290M in Q3 2022. 1 fund tracked by Wall St. Rank holds CCXI as of Q4 2022.

Goldman Sachs reported no remaining ChemoCentryx, Inc. position as of Q4 2022 after selling out during the quarter.
Goldman Sachs sold 5,616,301 ChemoCentryx, Inc. shares in Q4 2022, an estimated $290M.
Goldman Sachs first reported a position in ChemoCentryx, Inc. in Q3 2013 and held it in 31 quarters.
Goldman Sachs's ChemoCentryx, Inc. position peaked at $290M in Q3 2022.
1 fund tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2022.

Based on Goldman Sachs's 13F filing for Q4 2022, filed 13 Feb 2023.